SCHEMBL7419744

SCHEMBL7419744

CC[C@@H](O)[C@@H](CC1CCCCC1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.38
ATM Q13315 1/20 0.38
REN P00797 1/20 0.38
METAP2 P50579 1/20 0.38
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36
SLC1A3 P43003 2/20 0.36
SLC1A2 P43004 2/20 0.36
SLC1A1 P43005 2/20 0.36
CPB2 Q96IY4 1/20 0.36
GRN P28799 1/20 0.35
SORT1 Q99523 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7384272 0.86 ALDH1A1 (0.40) LTA4HRENMETAP2ALDH1A1KMT2A
SCHEMBL4196009 0.83 SLC1A3 (0.36) LTA4HMETAP2SLC1A3SLC1A2SLC1A1
SCHEMBL4196007 0.83 SLC1A3 (0.36) LTA4HMETAP2SLC1A3SLC1A2SLC1A1
SCHEMBL19690672 0.82 SLC1A3 (0.43) LTA4HSLC1A3SLC1A2SLC1A1GRN
SCHEMBL28948924 0.79 LTA4H (0.44) LTA4HSLC1A3SLC1A2SLC1A1CPB2
SCHEMBL21197392 0.79 LTA4H (0.44) LTA4HSLC1A3SLC1A2SLC1A1CPB2
SCHEMBL5319747 0.79 GRN (0.40) LTA4HMETAP2SLC1A3SLC1A2SLC1A1
SCHEMBL5319748 0.79 GRN (0.40) LTA4HMETAP2SLC1A3SLC1A2SLC1A1
SCHEMBL2243927 0.79 GRN (0.40) LTA4HMETAP2SLC1A3SLC1A2SLC1A1
SCHEMBL27237563 0.79 SMN1; SMN2 (0.42) LTA4HMETAP2ALDH1A1KMT2ASLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1019386-A1 REVERSE HYDROXAMATE DERIVATIVES AS METALLOPROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-07-19 EP disclosed
WO-1998038179-A1 REVERSE HYDROXAMATE DERIVATIVES AS METALLOPROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-09-03 WO disclosed